Aventis Pharma announced its 3QFY04 results last week. While the company has reported a marginal 2% growth in the topline, operating efficiencies have helped it record a sharp 57% rise in bottomline. For 9mFY04 also, the company has reported a 6% and 54% growth in net sales and net profit respectively. In this context, let us take a brief look at the company’s performance.
Results at a glance…
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (m)
Earnings per share (Rs)*
Aventis Pharma’s aggressive marketing strategy has helped it record a 7% growth in domestic sales during 3QFY03. The growth was fuelled by the good performance recorded by its strategic brands. Cardace (40%), Targocid (29%), Amarly (23%) and Clexane (17%) recorded impressive growth during the quarter. Among other major products, Combiflam (18% growth), Avil (10%) and Soframycin (9%) also continued to maintain leadership position in their respective segments. However, a 26% drop in export revenues stunted this growth. This was primarily on account of a drop in the overseas demand. Also, last year’s September quarter was exceptionally good for exports (34% growth over 3QFY02).
Despite flat growth in the topline, Aventis Pharma managed to improve its operating efficiency resulting in a 5.8 percentage points improvement in operating margins. This was primarily on account of a drop in the raw material cost as a percentage of sales from 56% in 3QFY03 to 51% in 3QFY04. Other income increased due to higher interest and dividend income. Thus, higher operating margins and a sharp increase in the net margins have helped the company record a 57% rise in net profits.
Continuing with its strategy of aggressive new product launches from its parent’s product portfolio, Aventis Pharma launched ‘Lantus’, world’s only 24-hour basal insulin in the anti – diabetics segment. Although, the company has separately disclosed Lantus’s performance in the current period, we expect it to be a top performer given its global success. ‘Lantus’ is likely to be one of the major growth drivers for the company going forward.
At Rs 506, Aventis Pharma is trading at a P/E of 13x its 9mFY04 earnings. Given the company's aggressive new product launches and the resultant new product portfolio, declining DPCO cover and focus on lifestyle segments, we remain positive about the long-term prospects of the company. However, although Aventis Pharma has been successfully charging a premium for its products, the sustainability of the same in view of the rising competition in the domestic market remains a concern as this could put pressure on its margins. For more on Aventis, view the Research Report
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407